Frederick Streeter Barrett, Ph.D.
Affiliations: | 2013- | Center for Psychedelic and Consciousness Research | Johns Hopkins University School of Medicine, Baltimore, MD, United States |
2013- | Behavioral Pharmacology Research Unit | Johns Hopkins University School of Medicine, Baltimore, MD, United States | |
2013- | Psychiatry and Behavioral Sciences | Johns Hopkins University School of Medicine, Baltimore, MD, United States |
Area:
Psychedelics, Music, Affective & Cognitive NeuroscienceWebsite:
https://hopkinspsychedelic.org/barrettGoogle:
"Frederick Streeter Barrett"Bio:
Frederick Barrett is a cognitive neuroscientist with training in behavioral pharmacology. Dr. Barrett has been conducting psychedelic research at Johns Hopkins University since 2013, and his research in heathy participants and in patients with mood and substance use disorders focuses on the psychological and neurological mechanisms underlying the enduring therapeutic and other effects of psychedelic drugs. In 2017, he received an NIH “R03” grant as Principal Investigator to investigate biological mechanisms of psilocybin effects, the first federally funded research since the 1970s administering a classic psychedelic to people with psychedelic effects as the primary focus. He developed the first comprehensive questionnaire to measure subjective aspects of challenging experiences encountered with psilocybin. He also published the first studies in humans characterizing the enduring effects of psilocybin on the brain (up to a month after psilocybin administration), the effects of psilocybin on a brain structure called the claustrum (which has been proposed to variously mediate consciousness and cognition), the effects of LSD on the brain's response to music, and the effects of the atypical hallucinogen salvinorin A on human brain network function. He is currently leading a clinical trial to investigate the use of psilocybin to treat patients with major depressive disorder and co-occurring alcohol use disorder, and he is leading a number of ongoing studies aimed at better understanding the psychological, biological, and neural mechanisms underlying therapeutic efficacy of psychedelic drugs.
(Show less)
Mean distance: 15.02 (cluster 14) | S | N | B | C | P |
Parents
Sign in to add mentorLauren B. Alloy | research assistant | 2002-2004 | Temple University | |
Robert W. Weisberg | research assistant | 2002-2004 | Temple University | |
Ruben C. Gur | research assistant | 2004-2007 | Penn | |
Petr Janata | grad student | 2007-2013 | UC Davis | |
(A Multi-Level Model of Music-Evoked Emotions: Stimulus Features, Personality, Familiarity, and Liking.) | ||||
Richard W. Robins | grad student | 2007-2013 | UC Davis (PsychTree) | |
J. Daniel Ragland | grad student | 2012-2013 | UC Davis | |
Roland Griffiths | post-doc | 2013- | Johns Hopkins Medical School |
Children
Sign in to add traineeBurke Q. Rosen | research assistant | 2008-2010 | UC Davis |
Ceyda Sayali | post-doc | Johns Hopkins Medical School | |
Manoj K. Doss | post-doc | 2018-2023 | Johns Hopkins Medical School |
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Levin AW, Lancelotta R, Sepeda ND, et al. (2024) The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. Plos One. 19: e0300501 |
Doss MK, Samaha J, Barrett FS, et al. (2023) Unique effects of sedatives, dissociatives, psychedelics, stimulants, and cannabinoids on episodic memory: A review and reanalysis of acute drug effects on recollection, familiarity, and metamemory. Psychological Review |
Nayak SM, Jackson H, Sepeda ND, et al. (2023) Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. Frontiers in Psychiatry. 14: 1199642 |
Gaddis A, Lidstone DE, Nebel MB, et al. (2023) Corrigendum to 'Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity': Neuroimage 2022 Oct 15;260:119434. Neuroimage. 274: 120130 |
Sayalı C, Barrett FS. (2023) The costs and benefits of psychedelics on cognition and mood. Neuron |
Barrett FS, Zhou Y, Carbonaro TM, et al. (2022) Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. Frontiers in Neuroergonomics. 2: 784576 |
Nikolaidis A, Lancelotta R, Gukasyan N, et al. (2022) Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. Journal of Affective Disorders. 324: 239-249 |
Doss MK, Barrett FS, Corlett PR. (2022) Skepticism about Recent Evidence That Psilocybin "Liberates" Depressed Minds. Acs Chemical Neuroscience |
Gaddis A, Lidstone DE, Nebel MB, et al. (2022) PSILOCYBIN INDUCES SPATIALLY CONSTRAINED ALTERATIONS IN THALAMIC FUNCTIONAL ORGANIZATON AND CONNECTIVITY. Neuroimage. 119434 |
McCulloch DE, Knudsen GM, Barrett FS, et al. (2022) Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. Neuroscience and Biobehavioral Reviews. 138: 104689 |